Comparison of dopamine transporter decline in a patient with Parkinson's disease and normal aging effect
Kenji Ishibashi1, Keiichi Oda1, Kiichi Ishiwata1
1Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0022, Japan.
Abstract:
We report serial dopamine transporter (DAT) positron emission tomography (PET) scanning in a patient with Parkinson's disease (PD). Six months after motor symptom onset, the patient was diagnosed with PD, Hoehn-Yahr stage 1 at age 71, and underwent DAT PET scanning at ages 71, 72, 74, and 75. Volumes-of-interest were placed on the ventral striatum (vST), pre-commissural dorsal caudate (preDCA), post-commissural caudate (postCA), pre-commissural dorsal putamen (preDPU), and post-commissural putamen (postPU); the results were compared to the age-related regression line created by using the data of 16 healthy subjects. For the patient, DAT availability in the vST, preDCA, postCA, preDPU, and postPU at the first scanning was 5.5%, 26.2%, 29.9%, 34.5%, and 60.2% lower, respectively, compared to the age-related regression line. The rates of DAT decline in the vST, preDCA, postCA, preDPU, and postPU were 5.3%, 5.4%, 8.5%, 6.2%, and 7.8% per year, respectively. The postPU is well known to be an initial region of DAT decline and be severely affected throughout the illness. If the decline follows an exponential pattern, in this case, DAT decline in the postPU is speculated to start about 10 years before the motor symptom onset.
More Related Videos
08:42Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease Genes
Published on: July 18, 2008
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Pharmacodynamics in Geriatric Patients: Effects of Age
Neural Regulation
